This program aims to develop anti-CD40L therapeutic monoclonal antibody for immuno-oncology. Anti-CD40L antibody targets CD40/TNFRSF5 receptors. It produces pleiotropic effects in various cells and biological processes, including immune response, thrombosis and atherogenesis. Learn more: Next-IO™ Anti-CD27 Monoclonal Antibody Program